Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN)

Barclays PLC grew its position in UroGen Pharma Ltd. (NASDAQ:URGN) by 409.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,778 shares of the company’s stock after acquiring an additional 48,040 shares during the quarter. Barclays PLC owned about 0.25% of UroGen Pharma worth $759,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets increased its stake in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after buying an additional 5,890 shares during the period. Intech Investment Management LLC purchased a new position in UroGen Pharma in the 3rd quarter worth about $155,000. Verition Fund Management LLC purchased a new position in UroGen Pharma in the 3rd quarter worth about $168,000. Finally, SG Americas Securities LLC purchased a new position in UroGen Pharma in the 3rd quarter worth about $179,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a report on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Stock Up 4.6 %

Shares of UroGen Pharma stock opened at $10.39 on Thursday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a 1 year low of $9.78 and a 1 year high of $20.70. The firm’s 50-day moving average is $11.50 and its two-hundred day moving average is $13.21. The stock has a market cap of $243.69 million, a price-to-earnings ratio of -3.30 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the prior year, the business posted ($0.68) earnings per share. As a group, research analysts expect that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.